Epizyme (EPZM) Gross Profit Margin starting from the second quarter 2022 to second quarter 2021, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Epizyme Inc.  (NASDAQ: EPZM)


Epizyme's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EPZM Gross Profit Margin (Jun 30 2022)
Q2 		(Mar 31 2022)
Q1 		(Dec 31 2021)
Q4 		(Sep 30 2021)
Q3 		(Jun 30 2021)
Q2
Y / Y Revenue Change 111.59 %
Seq. Revenue Change 216.56 %
Revenue In Millions $27.53
Gross Profit Margin 81.22 %
Gross Profit Margin Total Ranking # 533
Gross Profit In Millions $22.36
Y / Y Gross Profit Change 112.58 %
Seq. Gross Profit Change 269.02 %


Commenting Second Quarter 2022 Gross Profit Margin
Epizyme Inc. Gross Profit grew by 269.02 % in Q2 sequentially to 22 millions, while Revenue increased by 216.56 %, this led to improvement in the company's Gross Profit Margin to 81.22 % a new company high.


Observing second quarter 2022 results within Major Pharmaceutical Preparations industry 64 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 533, from total ranking in the previous quarter at 988.
Learn about Gross Margin
EPZM's Gross Profit Margin second quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 65
Healthcare Sector # 110
Overall # 520

Gross Profit Margin Statistics
High Average Low
81.22 % 67.51 % 54.65 %
(Jun 30 2022)   (Mar 31 2020)


EPZM Gross Income Trends • More of EPZM's Profitabilty Ratios • EPZM Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
EPZM's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
EPZM's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for EPZM's Competitors
Gross Profit Margin Profit Margin for Epizyme's Suppliers
Gross Profit Margin Profit Margin for EPZM's Customers

You may also want to know
EPZM's Annual Growth Rates EPZM's Profitability Ratios EPZM's Asset Turnover Ratio EPZM's Dividend Growth
EPZM's Roe EPZM's Valuation Ratios EPZM's Financial Strength Ratios EPZM's Gross Profit Growth
EPZM's Roa EPZM's Inventory Turnover Ratio EPZM's Growth Rates EPZM's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2022, within Major Pharmaceutical Preparations Industry Gross Profit MarginJun 30 2022 MRQ Gross ProfitJun 30 2022 MRQ Revenue
Ptc Therapeutics inc   99.82 %$ 165.226  Millions$ 165.526  Millions
Intercept Pharmaceuticals inc   99.57 %$ 71.448  Millions$ 71.757  Millions
Macrogenics Inc   99.31 %$ 25.827  Millions$ 26.007  Millions
Bridgebio Pharma Inc   99.05 %$ 73.046  Millions$ 73.746  Millions
Corcept Therapeutics Inc  98.73 %$ 102.070  Millions$ 103.386  Millions
Cormedix Inc   98.44 %$ 0.021  Millions$ 0.021  Millions
Global Blood Therapeutics Inc.  98.03 %$ 70.137  Millions$ 71.550  Millions
Acadia Pharmaceuticals Inc   98.02 %$ 131.896  Millions$ 134.563  Millions
Karyopharm Therapeutics Inc   97.63 %$ 38.740  Millions$ 39.679  Millions
Abvc Biopharma Inc   97.33 %$ 0.304  Millions$ 0.313  Millions
2seventy Bio Inc   97.30 %$ 13.118  Millions$ 13.482  Millions
Chemocentryx Inc.  96.59 %$ 22.723  Millions$ 23.526  Millions
Rigel Pharmaceuticals Inc  96.53 %$ 28.783  Millions$ 29.819  Millions
Ionis Pharmaceuticals Inc   96.45 %$ 129.046  Millions$ 133.791  Millions
Travere Therapeutics Inc   96.21 %$ 52.116  Millions$ 54.167  Millions
Zevra Therapeutics Inc   96.08 %$ 1.249  Millions$ 1.300  Millions
Myovant Sciences Ltd   95.78 %$ 111.577  Millions$ 116.492  Millions
Regeneron Pharmaceuticals Inc   94.78 %$ 2,708.000  Millions$ 2,857.200  Millions
Siga Technologies Inc  94.71 %$ 15.785  Millions$ 16.667  Millions
Ardelyx inc   94.54 %$ 2.388  Millions$ 2.526  Millions
Deciphera Pharmaceuticals Inc   94.46 %$ 30.695  Millions$ 32.494  Millions
Aurinia Pharmaceuticals Inc   94.33 %$ 26.592  Millions$ 28.191  Millions
United Therapeutics Corporation  93.64 %$ 437.200  Millions$ 466.900  Millions
Arvinas Inc   92.60 %$ 31.300  Millions$ 33.800  Millions
Cti Biopharma Corp   92.56 %$ 11.412  Millions$ 12.329  Millions
Agios Pharmaceuticals Inc   92.21 %$ 5.147  Millions$ 5.582  Millions
Silo Pharma Inc  91.91 %$ 0.017  Millions$ 0.018  Millions
Emmaus Life Sciences Inc   90.76 %$ 3.891  Millions$ 4.287  Millions
Ultragenyx Pharmaceutical Inc   90.74 %$ 81.073  Millions$ 89.343  Millions
Vanda Pharmaceuticals Inc   90.59 %$ 58.331  Millions$ 64.390  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.